Sp266
PANEL DISCUSSION
Date
May 6, 2023
Explore related products in the following collection:
Society: AGA
This session will provide an overview of present and future applications of artificial intelligence in the clinical practice of gastroenterology and hepatology, and highlight ethical, legal/regulatory, and equity considerations for use of AI in patient care. Practical strategies will be provided for mitigation of these concerns. The session includes a diverse roster of speakers representing perspectives gleaned by differences in age, gender, race and experience.
This session will provide an overview of present and future applications of artificial intelligence in the clinical practice of gastroenterology and hepatology, and highlight ethical, legal/regulatory, and equity considerations for use of AI in patient care. Practical strategies will be provided for mitigation of these concerns. The session includes a diverse roster of speakers representing perspectives gleaned by differences in age, gender, race and experience.
Presenters
Mayo Clinic
Massachusetts General Hospital
Tracks
Related Products
ETHICAL DIMENSIONS OF USING AI IN HEALTH CARE: IMPACTS ON DATA PRIVACY, PATIENT SAFETY, PATIENT PREFERENCE, AND PROVIDER AUTONOMY
This session will provide an overview of present and future applications of artificial intelligence in the clinical practice of gastroenterology and hepatology, and highlight ethical, legal/regulatory, and equity considerations for use of AI in patient care…
APPLICATIONS OF AI IN GI/HEPATOLOGY CLINICAL PRACTICE: PRESENT AND FUTURE
This session will provide an overview of present and future applications of artificial intelligence in the clinical practice of gastroenterology and hepatology, and highlight ethical, legal/regulatory, and equity considerations for use of AI in patient care…
INTRODUCTION
SOCIETY: AGA
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
